Incannex’s US redomicile is now complete – what’s next?

Healthcare

Incannex’s US redomicile is now complete – what’s next?

Incannex Healthcare is a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid drugs and psychedelic medicine therapies. These therapies are designed to target indications with unmet need, including obstructive sleep apnea, generalized anxiety disorder, trauma and inflammatory conditions.Following the company’s announcement in July 2023 that it intended to list all its shares on Nasdaq, Incannex received widespread support from its shareholders and option holders. Management anticipates that this strategic manoeuvre will yield several advantages, including heightened visibility of Incannex’s equity story, enhanced access to FDA resources and greater access to a large capital market. On 28 November Incannex completed its redomicile to the US.

In this interview, Incannex MD and CEO Joel Latham and CSO Mark Bleackley discuss the primary motivations behind the decision to redomicile to the US, the support from current and prospective shareholders, as well as the effect the move will have on the clinical trial pipeline and FDA approval.

Find out more about Incannex Healthcare’s investment case by reading Edison’s latest updates.

 

 

 

IMPORTANT DISCLOSURES

Edison offers investor relations, consulting and research publication services to paying clients. In accordance with Section 17(b) of the US Securities Act of 1933, please note the following important disclosures relating to Edison and its client relationship with Incannex Healthcare (the “Company”).

Edison is engaged by the Company on a paid basis for investor relations services and this communication relates to those services. In connection with its investor relations engagement by the Company, Edison’s standard fees are $20,000 per month. Additional compensation may have accrued since the publication of this notice.

In addition, Edison is engaged by the Company to separately provide investment research coverage of its stock. In connection with its investment research coverage, Edison’s standard fees are £60,000 pa. Additional compensation may have accrued since the publication of this notice. No compensation relating to Edison’s investment research coverage is in any way contingent upon any positive opinions or conclusions in its research reports.

Edison’s investor relations services are independent of its research services, although Edison’s investor relations activities may utilize published Edison research as a source, among others, in connection with its activities. Edison’s investor relations and investment research personnel regularly, but separately, interact with the Company. All source materials relating to any investor relations materials of Edison should be considered to be directly attributable to information provided to Edison by the Company or the third-party sources noted in the communication. While third-party information used in the publication of Edison’s communications is typically compiled from publicly available sources that are believed to be accurate, complete and reliable, Edison does not guarantee the accuracy or completeness of information contained therein, and typically does not independently verify such information.

NOTE THAT ALL INVESTMENTS ARE SUBJECT TO INHERENT RISK AND ANY INVESTMENT IN THE COMPANY IS SUBJECT TO SIGNIFICANT RISKS THAT SHOULD BE ASSESSED BY ANY INVESTOR AND THEIR ADVISORS. PLEASE CLOSELY REVIEW THE COMPANY’S AVAILABLE PUBLIC DISCLOSURES, INCLUDING RISK FACTORS FOR SPECIFIC CONSIDERATION, WHICH ARE AVAILABLE THROUGH THE COMPANY’S INVESTOR RELATIONS WEBSITE, LINKED ABOVE.

This communication may include forward-looking statements that are subject to risks and uncertainties. Factors that could cause a company’s actual results and financial condition to differ from expectations include, without limitation: political uncertainty, changes in general economic conditions that adversely affect the level of demand for the company’s products or services, changes in international and domestic financial markets and in the competitive environment, and other factors relating to the foregoing. All forward-looking statements relating to this communication are qualified in their entirety by this cautionary statement.

Edison is neither a FINRA-registered broker-dealer nor an SEC-registered investment adviser and does not provide any investment advisory or banking services. Edison’s investment research reports are bona fide publications of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. Edison does not offer or provide personal advice and its research provided is for informational purposes only. No mention of a particular security in any Edison communication constitutes a solicitation or recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison’s policies on personal dealing and conflicts of interest.

To find out more, get in touch

Latest

insight

The Illuminator – February 2024

Financials | insight

Alpha Bank – Investor Day 2023

insight

January insight: Mixed start to 2024

TMT

EQS Group: EKF 2023 QuickView

Cloud-based regtech saas company

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free